皮肤癌患者生活质量测量:EADV工作组文献综述与立场文件
欧洲皮肤病与性病学会(EADV)生活质量与患者相关结局、黑色素瘤及非黑色素瘤皮肤癌工作组对1980年以来皮肤癌患者健康相关生活质量(HRQoL)评估文献进行综述并形成立场文件。文件汇总了通用、皮肤病特异性、癌症特异性、皮肤癌特异性等各类量表的使用情况,推荐使用EORTC QLQ-C30(尤其晚期)、FACT-M和SCI,并指出其他量表验证经验有限。
要点
- 推荐皮肤癌患者HRQoL评估使用EORTC QLQ-C30,尤其疾病晚期。
- 黑色素瘤可用FACT-M,皮肤癌可用SCI,二者验证充分。
- 其他HRQoL量表基础验证尚可,但使用经验有限,暂不推荐。
核心结论
- EADV工作组推荐使用癌症特异性EORTC QLQ-C30(尤其晚期)、黑色素瘤特异性FACT-M和皮肤癌特异性SCI评估皮肤癌患者HRQoL。
- 其他HRQoL量表虽有良好基础验证,但因使用经验太有限,目前不予推荐。
- 皮肤病特异性HRQoL量表可用于评估皮肤相关问题对皮肤癌患者的影响。
研究设计与样本
- EADV生活质量与患者相关结局、黑色素瘤及非黑色素瘤皮肤癌工作组开展文献综述并发布立场文件。
- 文献检索纳入1980年以来包含皮肤癌对生活质量影响信息的出版物。
主要发现
- 皮肤癌患者HRQoL评估使用了通用、皮肤病特异性、癌症特异性、皮肤癌特异性、面部皮肤癌特异性、非黑色素瘤皮肤癌特异性、基底细胞癌特异性及黑色素瘤特异性问卷。
- HRQoL评估情境包括量表创建与验证、临床试验、皮肤癌与其他癌症或对照比较、治疗后评估、合并症、行为改变、QoL预测因素与生存、支持性照护需求、应对策略及癌症复发恐惧。
- 皮肤癌患者HRQoL评估最广泛使用的量表为EORTC QLQ-C30、FACT-M、SCI、SF-36和DLQI。
关键数值与推荐
- 推荐使用癌症特异性EORTC QLQ-C30,尤其在疾病晚期。
- 推荐使用黑色素瘤特异性FACT-M和皮肤癌特异性SCI问卷。
- 上述推荐量表已验证良好并在多项研究中使用。
临床怎么用
- 皮肤癌患者HRQoL评估可优先选用EORTC QLQ-C30、FACT-M和SCI等验证充分的量表。
- 皮肤病特异性HRQoL量表可用于评估皮肤相关问题对皮肤癌患者的影响。
- 其他HRQoL量表因使用经验有限,暂不作常规推荐。
局限性
- 其他HRQoL量表使用经验太有限,未能获得推荐。
- 工作组鼓励进一步研究验证HRQoL量表在不同皮肤癌阶段的应用,以给出更详细实用的评估建议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer (NMSC) present a review of the literature and position statement on health-related (HR) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology-specific, cancer-specific, SC-specific, facial SC-specific, NMSC-specific, basal cell carcinoma-specific and melanoma-specific QoL questionnaires have been used to assess HRQoL in SC patients. HRQoL was assessed in the context of creation and validation of the HRQoL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQoL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQoL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Melanoma (FACT-M), Skin Cancer Index (SCI), Short Form 36 Item Health Survey (SF-36) and the Dermatology Life Quality Index (DLQI). The TFs recommend the use of the cancer-specific EORTC QLQ-C30, especially in late stages of disease, and the melanoma-specific FACT-M and SC-specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQoL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology-specific HRQoL instruments can be used to assess the impact of skin-related problems in SC. The TFs encourage further studies to validate HRQoL instruments for use in different stages of SC, in order to allow more detailed practical recommendations on HRQoL assessment in SC.
引用
- Chernyshov PV, Lallas A, Tomas-Aragones L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. J Eur Acad Dermatol Venereol. 2019. PMID: 30963614. doi:10.1111/jdv.15487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。